VIREXX (REX): Together with its subsidiary, AltaRex Medical Corp. it develops novel therapeutics  for cancer and chronic viral infections based on three technology platforms, which include:

Antibody-based immunotherapy (AIT): Product from the AIT platform includes OvaRex MAb, for late-stage ovarian cancer, is in Phase 3 clinical trials.

 Targeted autothrombogenic cancer therapy (T-ACT): Its product from the T-ACT platform is Occlusin 50 Injection, which is in Phase 1 clinical trial for the treatment of solid liver tumors. T

 Chimigen platform: Products include HepaVaxx B, a therapeutic vaccine for chronic hepatitis B infection; and HepaVaxx C, a therapeutic vaccine for the treatment of chronic hepatitis C infection.

Strategic alliance: With United Therapeutics Corporation for the development and commercialization of OvaRex MAb and four other monoclonal antibodies worldwide.

ViRexx Medical was co-founded by Antoine A. Noujaim and Lorne J. Tyrrell in June 2001 under the name ViRexx Corporation. Later, it changed its name to ViRexx Research, Inc. in October 2001; and to ViRexx Medical Corp. in 2003. The company is headquartered in Edmonton, Canada.